Identification
- Summary
Fluorescein is a dye used in angiography or angioscopy of the iris and retina.
- Brand Names
- Ak-fluor, Altafluor, Diofluor, Fluorescite, Fluress
- Generic Name
- Fluorescein
- DrugBank Accession Number
- DB00693
- Background
A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Fluorescein (DB00693)
- Weight
- Average: 332.3063
Monoisotopic: 332.068473494 - Chemical Formula
- C20H12O5
- Synonyms
- 3,6-fluorandiol
- 3',6'-dihydroxyfluoran
- 9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone
- 9-(o-carboxyphenyl)-6-hydroxy-3H-xanthen-3-one
- C.I. Solvent Yellow 94
- D and C Yellow No. 7
- D&C Yellow No. 7
- Fluorescein
- Fluoresceina
- Fluoresceína
- Fluoresceine
- Fluoreszein
- Japan Yellow 201
- Resorcinolphthalein
- Solvent Yellow 94
- Yellow fluorescein
- External IDs
- CI 45350:1
Pharmacology
- Indication
For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to manage Peritoneal dialysis Combination Product in combination with: Magnesium chloride (DB09407), Calcium chloride (DB01164), Lactic acid (DB04398) •••••••••••• Prophylaxis of Pneumocystis jirovecii pneumonia •••••••••••• ••••••• •• ••• •• •••• •••••••• •• •••••••••••• •••••••• •••••••••• ••• ••••••••• •••••••••• •••• •••••••••• ••••• • ••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Fluorescein sodium is used extensively as a diagnostic tool in the field of ophthalmology. Fluorescein is a fluorescent compound or fluorophore having a maximum absorbance of 494 m and an emission maximum of 521 nm. The yellowish-green fluorescence of the compound can be used to demarcate the vascular area under observation, distinguishing it from adjacent areas. It is applied topically in the form of a drop or it can be injected intravenously to produce a fluorescein angiogram. Topical fluorescein is a useful tool in the diagnosis of corneal abrasions, corneal ulcers, herpetic corneal infections, and dry eye. Fluorescein angiography is used to diagnose and categorize macular degeneration, diabetic retinopathy, inflammatory intraocular conditions, and intraocular tumors.
Target Actions Organism NIg kappa chain V-II region RPMI 6410 otherHumans NDNA otherHumans - Absorption
Rapidly distributed
- Volume of distribution
- 0.5 L/kg
- Protein binding
85%
- Metabolism
- Not Available
- Route of elimination
Fluorescein and its metabolites are mainly eliminated via renal excretion.
- Half-life
Not Available
- Clearance
- renal cl=1.75 mL/min/kg [After IV administration]
- hepatic cl=1.50 mL/min/kg [After IV administration]
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The excretion of Fluorescein can be decreased when combined with Acetazolamide. Acetylsalicylic acid The excretion of Fluorescein can be decreased when combined with Acetylsalicylic acid. Acyclovir The excretion of Fluorescein can be decreased when combined with Acyclovir. Adefovir dipivoxil The excretion of Adefovir dipivoxil can be decreased when combined with Fluorescein. Aminohippuric acid The excretion of Fluorescein can be decreased when combined with Aminohippuric acid. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Fluorescein sodium 93X55PE38X 518-47-8 NJDNXYGOVLYJHP-UHFFFAOYSA-L - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ak-fluor Injection 250 mg/1mL Intravenous Akorn 2008-10-01 Not applicable US 
Ak-fluor Injection 100 mg/1mL Intravenous Akorn 2008-10-01 Not applicable US Ak-fluor Injection 100 mg/1mL Intravenous A-S Medication Solutions 2008-10-01 Not applicable US Angiofluor Injection, solution 250 mg/1mL Intravenous Alliance Inj LLC 2000-12-01 2012-02-29 US Angiofluor Lite Injection, solution 100 mg/1mL Intravenous Alliance Inj LLC 2001-10-01 2012-02-29 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Fluorescein Injection 250 mg/1mL Intravenous Nexus Pharmaceuticals LLC 2023-10-24 Not applicable US Fluorescein Injection 500 mg/1mL Intravenous Nexus Pharmaceuticals LLC 2023-10-24 Not applicable US Odan-fluorescein Liquid 250 mg / mL Intravenous Odan Laboratories Ltd 1985-12-31 Not applicable Canada 
Odan-fluorescein Solution 100 mg / mL Intravenous Odan Laboratories Ltd 1984-12-31 Not applicable Canada Odan-fluorets Strip 1 mg Ophthalmic Odan Laboratories Ltd 1986-12-31 Not applicable Canada - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image FLUORESCEIN NOVARTIS (100 MG/ML) Injection, solution 100 mg/1ml Ophthalmic บริษัท ซิลลิค ฟาร์มา จำกัด 2015-08-31 Not applicable Thailand 
FLUORETS STERILE OPHTHALMIC STRIP 1 mg Strip 1 mg Ophthalmic BAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED 1990-05-04 Not applicable Singapore 
MINIMS FLUORESCEIN SODIUM EYE DROPS 2% w/v Solution 2 % w/v Ophthalmic BAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED 1990-05-04 Not applicable Singapore - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Altafluor Fluorescein sodium (2.5 mg/1mL) + Oxybuprocaine hydrochloride (4 mg/1mL) Solution Ophthalmic Altaire Pharmaceuticals Inc. 2018-03-01 Not applicable US Altafluor Fluorescein sodium (2.5 mg/1mL) + Oxybuprocaine hydrochloride (4 mg/1mL) Solution Ophthalmic Altaire Pharmaceuticals Inc. 2017-01-01 2018-04-19 US Fluorescein Sodium & Benoxinate Hydrochloride Ophthalmic Solution, USP Fluorescein sodium (0.25 %) + Oxybuprocaine hydrochloride (0.4 %) Solution Ophthalmic Bausch & Lomb Inc 1998-10-27 Not applicable Canada Fluorescein Sodium and Benoxinate Hydrochloride Fluorescein sodium (2.6 mg/1mL) + Oxybuprocaine hydrochloride (4.4 mg/1mL) Solution / drops Ophthalmic Bausch & Lomb Incorporated 2020-03-20 Not applicable US Fluorescein Sodium and Benoxinate Hydrochloride Fluorescein sodium (2.6 mg/1mL) + Oxybuprocaine hydrochloride (4.4 mg/1mL) Solution / drops Ophthalmic Oceanside Pharmaceuticals 2021-03-25 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Angiofluor Fluorescein sodium (250 mg/1mL) Injection, solution Intravenous Alliance Inj LLC 2000-12-01 2012-02-29 US Angiofluor Lite Fluorescein sodium (100 mg/1mL) Injection, solution Intravenous Alliance Inj LLC 2001-10-01 2012-02-29 US Angiofluor Lite Fluorescein sodium (250 mg/1mL) Injection, solution Intravenous Alliance Inj LLC 2002-03-01 2012-02-29 US BioGlo Fluorescein sodium (1 mg/1mg) Strip Ophthalmic HUB Pharmaceuticals, Inc. 2012-04-01 Not applicable US BioGlo Fluorescein sodium (1 mg/1mg) Strip Ophthalmic REMEDYREPACK INC. 2014-08-04 2017-06-24 US
Categories
- ATC Codes
- S01JA01 — FluoresceinS01JA51 — Fluorescein, combinations
- Drug Categories
- BSEP/ABCB11 Substrates
- Coloring Agents
- Colouring Agents
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Diagnostic Agents
- Diagnostic Dye
- Diagnostic Uses of Chemicals
- Fluoresceins
- Fluorescent Dyes
- Heterocyclic Compounds, Fused-Ring
- Indicators and Reagents
- Laboratory Chemicals
- Luminescent Agents
- OAT1/SLC22A6 inhibitors
- OAT1/SLC22A6 Substrates
- OAT3/SLC22A8 Substrates
- Ocular Disorders
- Ophthalmologicals
- Other Diagnostics
- Sensory Organs
- Spiro Compounds
- Xanthenes
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as xanthenes. These are polycyclic aromatic compounds containing a xanthene moiety, which consists of two benzene rings joined to each other by a pyran ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzopyrans
- Sub Class
- 1-benzopyrans
- Direct Parent
- Xanthenes
- Alternative Parents
- Diarylethers / Phthalides / Benzofuranones / Isobenzofurans / 1-hydroxy-2-unsubstituted benzenoids / Lactones / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organic oxides show 1 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / Aromatic heteropolycyclic compound / Benzenoid / Benzofuranone / Carboxylic acid derivative / Carboxylic acid ester / Diaryl ether / Ether / Hydrocarbon derivative / Isobenzofuran show 10 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- xanthene dye, polyphenol, gamma-lactone (CHEBI:31624)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- TPY09G7XIR
- CAS number
- 2321-07-5
- InChI Key
- GNBHRKFJIUUOQI-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H
- IUPAC Name
- 3',6'-dihydroxy-3H-spiro[2-benzofuran-1,9'-xanthen]-3-one
- SMILES
- OC1=CC=C2C(OC3=CC(O)=CC=C3C22OC(=O)C3=C2C=CC=C3)=C1
References
- Synthesis Reference
Richard T. Dean, Conrad P. Dorn, Jr., Tsung-Ying Shen, "Fluorescein esters and ethers and the preparation thereof." U.S. Patent US4304720, issued January, 1972.
US4304720- General References
- Noga EJ, Udomkusonsri P: Fluorescein: a rapid, sensitive, nonlethal method for detecting skin ulceration in fish. Vet Pathol. 2002 Nov;39(6):726-31. [Article]
- External Links
- Human Metabolome Database
- HMDB0014831
- KEGG Drug
- D01261
- PubChem Compound
- 16850
- PubChem Substance
- 46504703
- ChemSpider
- 15968
- BindingDB
- 50237588
- 25138
- ChEBI
- 31624
- ChEMBL
- CHEMBL1057
- ZINC
- ZINC000003860453
- PharmGKB
- PA164746009
- PDBe Ligand
- FLU
- RxList
- RxList Drug Page
- Wikipedia
- Fluorescein
- MSDS
- Download (73 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Diagnostic Ureteral Patency 1 4 Recruiting Diagnostic Retinal Diseases 1 4 Suspended Diagnostic Fluorescein angiography 1 4 Terminated Treatment Adult Intracranial Neoplasm / Vascular: Intracranial 1 4 Unknown Status Diagnostic Gastric Intestinal Metaplasia 1
Pharmacoeconomics
- Manufacturers
- Novartis pharmaceuticals corp
- Alcon inc
- Packagers
- Accutome Inc.
- Akorn Inc.
- Alcon Laboratories
- Altaire Pharmaceuticals
- Amend
- Amphastar Pharmaceuticals
- Bausch & Lomb Inc.
- Cardinal Health
- Conta Care Ophthalmics and Diagnostics
- Deca Pharmaceuticals LLC
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Eye Care and Cure Corp.
- Eye Supply Usa Inc.
- HUB Pharmaceuticals
- Nomax Inc.
- Ocusoft
- OMJ Pharmaceuticals
- Physicians Total Care Inc.
- Southwood Pharmaceuticals
- Taylor Pharmaceuticals
- Wilson Ophthalmic Corp.
- Dosage Forms
Form Route Strength Injection Intravenous 100 mg/1mL Injection Intravenous 250 mg/1mL Strip Ophthalmic 1 mg/1mg Strip Ophthalmic 0.12 mg/1 Injection, solution Ophthalmic Injection Intravenous 500 mg/1mL Solution Intravenous 250 mg / mL Solution / drops Ophthalmic Injection, solution Intravenous 100 mg/1mL Injection, solution Intravenous 250 mg/1mL Injection, solution Intravenous 0.5 g/5ml Solution Conjunctival; Ophthalmic 250 mg Solution Intravenous 100 mg Injection, solution Intravenous 1 G/5ML Injection, solution Ophthalmic 100 mg/1mL Solution Intravenous 10 % Injection, solution Ophthalmic 10 % Liquid Parenteral 25 % Injection, solution Intravenous Strip Ophthalmic 1 mg Solution / drops Ophthalmic Liquid Ophthalmic Solution Ophthalmic Strip Ophthalmic 1.0 mg/1 Liquid Intravenous 25 % Strip Ophthalmic 0.6 mg/1 Strip Ophthalmic 1 mg/1 Solution / drops Ophthalmic 2 % w/v Solution Ophthalmic 2 % w/v Solution / drops Ophthalmic; Topical Injection, solution Intravenous 500 mg/5ml Liquid Intravenous 250 mg / mL Solution Intravenous 100 mg / mL - Prices
Unit description Cost Unit Fluorescein 2% droptainer 12.0USD ml Fluorescite 10% ampul 5.99USD ml Fluorescein lite 25% vial 4.29USD ml Ak-fluor 25% vial 3.9USD ml Fluorescein sodium 25% vial 2.4USD ml Fluorescein lite 10% vial 1.72USD ml Ak-fluor 10% vial 1.56USD ml Fluorescein sodium 10% vial 0.96USD ml Fluorescein powder 0.08USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US10293047 No 2019-05-21 2037-11-15 US US10632197 No 2020-04-28 2037-11-15 US US10842872 No 2020-11-24 2037-11-15 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 315 dec °C PhysProp water solubility 600 mg/mL (sodium salt) Not Available logP 3.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0255 mg/mL ALOGPS logP 2.64 ALOGPS logP 3.88 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) 8.72 Chemaxon pKa (Strongest Basic) -3.7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 75.99 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 91.22 m3·mol-1 Chemaxon Polarizability 33.14 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9542 Blood Brain Barrier + 0.8803 Caco-2 permeable - 0.8076 P-glycoprotein substrate Substrate 0.5063 P-glycoprotein inhibitor I Non-inhibitor 0.9612 P-glycoprotein inhibitor II Non-inhibitor 0.9393 Renal organic cation transporter Non-inhibitor 0.8702 CYP450 2C9 substrate Non-substrate 0.8032 CYP450 2D6 substrate Non-substrate 0.8972 CYP450 3A4 substrate Non-substrate 0.6669 CYP450 1A2 substrate Non-inhibitor 0.6827 CYP450 2C9 inhibitor Inhibitor 0.7325 CYP450 2D6 inhibitor Non-inhibitor 0.8381 CYP450 2C19 inhibitor Non-inhibitor 0.7311 CYP450 3A4 inhibitor Inhibitor 0.5166 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7479 Ames test Non AMES toxic 0.9133 Carcinogenicity Non-carcinogens 0.9437 Biodegradation Not ready biodegradable 0.9431 Rat acute toxicity 2.7602 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9805 hERG inhibition (predictor II) Non-inhibitor 0.9481
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 187.9563005 predictedDarkChem Lite v0.1.0 [M-H]- 176.1639455 predictedDarkChem Lite v0.1.0 [M-H]- 188.0374005 predictedDarkChem Lite v0.1.0 [M-H]- 178.7641 predictedDeepCCS 1.0 (2019) [M+H]+ 188.0805005 predictedDarkChem Lite v0.1.0 [M+H]+ 178.0169652 predictedDarkChem Lite v0.1.0 [M+H]+ 188.5183005 predictedDarkChem Lite v0.1.0 [M+H]+ 181.1221 predictedDeepCCS 1.0 (2019) [M+Na]+ 188.5961005 predictedDarkChem Lite v0.1.0 [M+Na]+ 191.7176545 predictedDarkChem Lite v0.1.0 [M+Na]+ 188.8091005 predictedDarkChem Lite v0.1.0 [M+Na]+ 188.00163 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Other
- General Function
- Antigen binding
- Specific Function
- Not Available
- Gene Name
- Not Available
- Uniprot ID
- P06310
- Uniprot Name
- Ig kappa chain V-II region RPMI 6410
- Molecular Weight
- 14706.62 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
No
Other
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Estevez-Torres A, Gosse C, Le Saux T, Allemand JF, Croquette V, Berthoumieux H, Lemarchand A, Jullien L: Fourier analysis to measure diffusion coefficients and resolve mixtures on a continuous electrophoresis chip. Anal Chem. 2007 Nov 1;79(21):8222-31. Epub 2007 Sep 25. [Article]
- Huang YM, Qi YJ, Zhu YL, Tong DY, Wu XY: [Polymorphism of 7 Y-STR loci in Chinese populations by multiplex PCR genotyping using fluorescein-labeled primers]. Yi Chuan. 2007 Oct;29(10):1214-22. [Article]
- Pennathur S, Baldessari F, Santiago JG, Kattah MG, Steinman JB, Utz PJ: Free-solution oligonucleotide separation in nanoscale channels. Anal Chem. 2007 Nov 1;79(21):8316-22. Epub 2007 Sep 21. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- Curator comments
- Substrate profile was investigated in vitro using CHO and HEK293 cells.
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [Article]
- VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Transporter activity
- Specific Function
- Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
- Gene Name
- ABCB11
- Uniprot ID
- O95342
- Uniprot Name
- Bile salt export pump
- Molecular Weight
- 146405.83 Da
References
- Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Transporter activity
- Specific Function
- Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
- Gene Name
- ABCC1
- Uniprot ID
- P33527
- Uniprot Name
- Multidrug resistance-associated protein 1
- Molecular Weight
- 171589.5 Da
References
- Sun H, Johnson DR, Finch RA, Sartorelli AC, Miller DW, Elmquist WF: Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55